These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36974332)

  • 1. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
    Alshehri FS
    Drug Des Devel Ther; 2023; 17():851-861. PubMed ID: 36974332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacology and toxicology of tramadol and tapentadol.
    Faria J; Barbosa J; Moreira R; Queirós O; Carvalho F; Dinis-Oliveira RJ
    Eur J Pain; 2018 May; 22(5):827-844. PubMed ID: 29369473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action.
    Caputi FF; Nicora M; Simeone R; Candeletti S; Romualdi P
    Minerva Med; 2019 Feb; 110(1):62-78. PubMed ID: 30667206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan.
    Sugiyama Y; Kataoka T; Tasaki Y; Kondo Y; Sato N; Naiki T; Sakamoto N; Akechi T; Kimura K
    Jpn J Clin Oncol; 2018 Apr; 48(4):362-366. PubMed ID: 29506199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients.
    Roulet L; Rollason V; Desmeules J; Piguet V
    Drugs; 2021 Jul; 81(11):1257-1272. PubMed ID: 34196947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is tapentadol different from classical opioids? A review of the evidence.
    Langford RM; Knaggs R; Farquhar-Smith P; Dickenson AH
    Br J Pain; 2016 Nov; 10(4):217-221. PubMed ID: 27867511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?
    Caraci F; Coluzzi F; Marinangeli F; Mercadante S; Rinonapoli G; Romualdi P; Nicora M; Dickenson AH
    Curr Med Res Opin; 2020 Jun; 36(6):1015-1024. PubMed ID: 32216591
    [No Abstract]   [Full Text] [Related]  

  • 13. Is tapentadol an advance on tramadol?
    Guay DR
    Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
    Tzschentke TM; Christoph T; Kögel BY
    CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders.
    Severtson SG; Gurrola MC; Parrino MW; Ellis MS; Cicero TJ; Iwanicki JL; Dart RC
    J Opioid Manag; 2023; 19(5):445-453. PubMed ID: 37968978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology update: tapentadol for neuropathic pain.
    Pierce DM; Shipstone E
    Am J Hosp Palliat Care; 2012 Dec; 29(8):663-6. PubMed ID: 22310021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapentadol - A representative of a new class of MOR-NRI analgesics.
    Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
    Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol for the management of cancer pain in adults: an update.
    Boland JW
    Curr Opin Support Palliat Care; 2023 Jun; 17(2):90-97. PubMed ID: 36919687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tapentadol is a new, strongly efficative analgeticum with dual effect mechanisms].
    Staahl C; Drewes AM; Jensen NH
    Ugeskr Laeger; 2011 Jun; 173(25):1796-9. PubMed ID: 21689507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapentadol Prolonged Release: A Review in Pain Management.
    Deeks ED
    Drugs; 2018 Nov; 78(17):1805-1816. PubMed ID: 30471002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.